Aducanumab Opinion

Abstract

Aducanumab (brand name Aduhelm) is the first FDA-approved, pharmacologic treatment for Alzheimer’s disease (AD)but many uncertainties remain regarding both efficacy and safety. Of paramount concern areassociated adverse effects including cerebral edema and hemorrhage which prompted a post-approval study. Aside from safety concerns, withdrawal from the market may occur if it fails to demonstrate efficacy as described in pre-approval reports

Authors and Affiliations

Asia Filatov, MD,Jonathan T. Grossman DO

Keywords

Related Articles

Gestational Trophoblastic Disease Metastasized to the Vagina: Case Report

Background:Gestational trophoblastic disease is caused by placenta abnormalities and can metastasize in several places outside the uterus, including the vagina. Its criteria are based on physical examin...

Giant Splenomegaly Secondary to Chronic Myeloid Leukemia: Case Report

The abnormal growth of the spleen is called splenomegaly, this finding is a challenge when determining its etiology for the first contact physician due to the wide range of diagnostic possibilities. Infecti...

Perioperative Management of the Facial Wounds with Insight of Scar Prevention

Human face is the front side of a head which functions most of all for individual identity. Global culture agrees that scarring on the face reducesattractiveness to the opposite sex; and it drives everyone with a wound...

Gluteal Fold V-Y Advancement Flap for Genital Reconstruction following Radical Vulvectomy with Bilateral Inguinofemoral Lymphadenectomy in Vulvar Cancer: A Case Report

Background: Vulvar cancer is a rare malignancy representing about 4% of all genital cancers in women. Historically, the gold standard for treatment of squamous cell carcinoma of the vulva was en bloc radical vulvectomy w...

Role of Surgical Debridement in Wound Management

A wound is a disturbance of the skin's and soft tissue architecture's normal structure and function. Prior to further wound treatment, wounds with devitalized tissue, contamination, or leftover...

Download PDF file
  • EP ID EP733075
  • DOI 10.47191/ijmscrs/v2-i8-12
  • Views 15
  • Downloads 0

How To Cite

Asia Filatov, MD, Jonathan T. Grossman DO (2022). Aducanumab Opinion. International Journal Of Medical Science And Clinical Research Studies, 2(08), -. https://europub.co.uk/articles/-A-733075